https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment. CEO … Read more
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Novo Nordisk‘s hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from … Read more
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4